Emcure Pharmaceuticals Limited (BOM:544210)
India · Delayed Price · Currency is INR 1,515.95
+32.50 (2.19%)
At close: Feb 6, 2026
Emcure Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 6,813 | 4,982 | 5,320 | 6,622 | 3,921 |
Depreciation & Amortization | 3,743 | 3,032 | 2,512 | 2,348 | 3,137 |
Other Amortization | 97.98 | 92.56 | 89.04 | 100.28 | 96.1 |
Loss (Gain) From Sale of Assets | -382.35 | -71.92 | 3.33 | 4.08 | -4.23 |
Asset Writedown & Restructuring Costs | - | - | - | - | 436.95 |
Loss (Gain) From Sale of Investments | -58.04 | -25.32 | -1.21 | - | - |
Stock-Based Compensation | 19.89 | 39.67 | 52.76 | 57.16 | 63.48 |
Other Operating Activities | 2,526 | 2,419 | 2,415 | 1,469 | 4,573 |
Change in Accounts Receivable | -1,434 | -1,506 | -3,398 | -1,729 | -3,301 |
Change in Inventory | -4,067 | -267.61 | 663.85 | -3,072 | -3,413 |
Change in Accounts Payable | 1,702 | 1,543 | -391.8 | 3,157 | 2,315 |
Change in Other Net Operating Assets | -443.61 | 736.2 | 203.54 | -1,276 | 1,053 |
Operating Cash Flow | 8,517 | 10,972 | 7,469 | 7,682 | 7,044 |
Operating Cash Flow Growth | -22.38% | 46.91% | -2.78% | 9.05% | 40.80% |
Capital Expenditures | -2,218 | -2,758 | -3,906 | -3,782 | -1,254 |
Sale of Property, Plant & Equipment | 306.01 | 315.37 | 12.75 | 31.21 | 125.14 |
Cash Acquisitions | - | -3,451 | - | -2,751 | -1,116 |
Sale (Purchase) of Intangibles | -1,852 | -313.6 | -127.67 | -187.87 | -202.65 |
Investment in Securities | 2,592 | -1,098 | -708.36 | -1,308 | -147.22 |
Other Investing Activities | 231.44 | 179.46 | 152.4 | 109.49 | 75.81 |
Investing Cash Flow | -940.01 | -7,125 | -4,577 | -7,888 | -2,518 |
Short-Term Debt Issued | - | 1,025 | 976.79 | 1,759 | - |
Long-Term Debt Issued | - | 5,474 | 3,576 | 3,714 | 5,775 |
Total Debt Issued | - | 6,500 | 4,553 | 5,473 | 5,775 |
Short-Term Debt Repaid | -5,225 | - | - | - | -981.67 |
Long-Term Debt Repaid | -9,420 | -5,310 | -3,777 | -4,814 | -4,548 |
Total Debt Repaid | -14,645 | -5,310 | -3,777 | -4,814 | -5,529 |
Net Debt Issued (Repaid) | -14,645 | 1,190 | 775.24 | 659.17 | 245.66 |
Issuance of Common Stock | 7,792 | 76.6 | - | - | - |
Common Dividends Paid | - | -542.55 | -361.71 | -542.55 | -180.85 |
Other Financing Activities | -1,287 | -2,366 | -1,868 | -1,635 | -1,954 |
Financing Cash Flow | -8,140 | -1,642 | -1,454 | -1,519 | -1,889 |
Foreign Exchange Rate Adjustments | -20.49 | -20.02 | -1.28 | 1.86 | -46.17 |
Miscellaneous Cash Flow Adjustments | - | - | -100 | 2,141 | - |
Net Cash Flow | -583.02 | 2,185 | 1,336 | 418.7 | 2,591 |
Free Cash Flow | 6,299 | 8,215 | 3,563 | 3,900 | 5,790 |
Free Cash Flow Growth | -23.32% | 130.58% | -8.65% | -32.65% | 50.40% |
Free Cash Flow Margin | 7.98% | 12.34% | 5.95% | 6.66% | 11.50% |
Free Cash Flow Per Share | 33.68 | 45.42 | 19.70 | 21.57 | 32.02 |
Cash Interest Paid | 1,287 | 2,082 | 1,786 | 1,553 | 1,845 |
Cash Income Tax Paid | 2,469 | 2,237 | 2,005 | 3,112 | 2,004 |
Levered Free Cash Flow | 2,777 | 3,670 | 1,625 | 2,297 | 5,053 |
Unlevered Free Cash Flow | 3,591 | 4,940 | 2,781 | 3,216 | 5,765 |
Change in Working Capital | -4,243 | 505.17 | -2,922 | -2,919 | -3,346 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.